Michael J. Forrest - Concepedia

Author

Michael J. Forrest

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

Edward A. O’Neill, Michael Forrest, Michael J Forrest, Michael J. Forrest

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Cytel (United States)

About

Michael J. Forrest is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	31	1.4K
2	Natural Sciences	8	8	374
3	Health Sciences	2	2	59
4	Public Health	1	1	40
5	Allergy	1	1	118

Michael J. Forrest

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2 Catherine Abbadie, Jill A. Lindia, Anne Marie Cumiskey, Proceedings of the National Academy of Sciences	2003	585
Peroxisome Proliferator-Activated Receptors γ and α Mediate in Vivo Regulation of Uncoupling Protein (UCP-1, UCP-2, UCP-3) Gene Expression Linda Kelly, Pasquale P. Vicario, G M Thompson, Endocrinology	1998	271
Role of the melanocortin-4 receptor in metabolic rate and food intake in mice Airu S. Chen, Joseph M. Metzger, Myrna E. Trumbauer, Transgenic Research	2000	246
Human β3-adrenergic receptor agonists containing 1,2,3-triazole-substituted benzenesulfonamides Linda Brockunier, Emma R. Parmee, Hyun Ok, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinePharmacological AgentExperimental PharmacologyPharmacotherapy	2000	199
Sphingosine-1-Phosphate Receptor Agonism Impairs the Efficiency of the Local Immune Response by Altering Trafficking of Naive and Antigen-Activated CD4+ T Cells Jenny Xie, Naomi Nomura, Sam L. Koprak, The Journal of Immunology Adaptive Immune SystemT-regulatory CellImmunologyImmunologic MechanismAntigen Processing	2003	118
Discovery of Potent 3,5-Diphenyl-1,2,4-oxadiazole Sphingosine-1-phosphate-1 (S1P<sub>1</sub>) Receptor Agonists with Exceptional Selectivity against S1P<sub>2</sub> and S1P<sub>3</sub> Zhen Li, Weirong Chen, Jeffrey J. Hale, Journal of Medicinal Chemistry Drug TargetImmunologyPharmacotherapyS1p3 Receptor AgonismMolecular Pharmacology	2005	99
Sphingosine-1-Phosphate Agonists Increase Macrophage Homing, Lymphocyte Contacts, and Endothelial Junctional Complex Formation in Murine Lymph Nodes Irwin Singer, Min Tian, L. Alexandra Wickham, The Journal of Immunology ImmunologyImmune RegulationImmunologic MechanismSinus VolumeImmunotherapy	2005	89
Novel <i>N-</i>Arylpyrazolo[3,2-<i>c</i>]-Based Ligands for the Glucocorticoid Receptor: Receptor Binding and in Vivo Activity Amjad Ali, Christopher F. Thompson, James M. Balkovec, Journal of Medicinal Chemistry ImmunologyPharmacotherapyGlucocorticoidGlucocorticoid ReceptorMedicinal Chemistry	2004	66
Discovery of a Potent, Orally Bioavailable β<sub>3</sub> Adrenergic Receptor Agonist, (<i>R</i>)-<i>N</i>-[4-[2-[[2-Hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide Robert J. Mathvink, J. Samuel Tolman, Dawn Chitty, Journal of Medicinal Chemistry Molecular PharmacologyPharmaceutical ScienceSubstituted Thiazole BenzenesulfonamidePharmacological StudyBiochemistry	2000	63
Discovery of a Biaryl Cyclohexene Carboxylic Acid (MK-6892): A Potent and Selective High Affinity Niacin Receptor Full Agonist with Reduced Flushing Profiles in Animals as a Preclinical Candidate Hong C. Shen, Fa‐Xiang Ding, Subharekha Raghavan, Journal of Medicinal Chemistry Potent Niacin ReceptorExcellent Receptor ActivityPharmacotherapyExperimental PharmacologyMedicinal Chemistry	2010	57

Page 1